Abstract: Objective：To discuss the effect of liraglutide on glycemic control and reduction of cardiometabolic risk factors in patients with newly diagnosed type 2 diabetes (T2DM) and metabolic syndrome (MS). Methods：Sixtythree cases with newly diagnosed T2DM (HbA1c 7.5%-11%) and MS were selected, and randomly divided 1∶1 into metformin group (0.85 g,oral administration, two times a day) and liraglutide group (1.2 mg, subcutaneous injection, one time a day). The primary endpoint was change in metabolic parameters. Results：Sixty patients completed the study. There was a reduction in weight，body mass index，waist circumference，fasting glycemia，HbA1c, total and LDLcholesterol, and triglycerides in both groups（P＜0.01）.Liraglutide was superior to metformin in reducing weight, BMI, and waist circumference （P＜0.05）.There was no adverse effect in two groups. Conclusions：Liraglutide is associated with improved glycemic control and reduction of cardiometabolic risk factors in newly diagnosed T2DM and the MS.